This month, we have learned about multiple approaches to myopia control including atropine drop therapy, MiSight soft contact lenses, and orthokeratology. Now it is time to learn more about the newest modality: Stellest spectacle lenses by Essilor.
Stellest gained FDA approval on September 25, 2025, and is already clinically available. The lens design utilizes the familiar myopia management concept of combining central refractive error correction with peripheral myopic defocus. This defocus is achieved through Essilor’s Highly Asperical Lenslet Target (H.A.L.T.) technology that distributes 1,021 aspherical “lenslets” in a circular design of 11 rings through the lens to control progression in all gazes.
Clinical data is showing promise for this technology: Essilor boasts a 71% reduction in myopia progression and a 53% reduction in axial elongation over 2 years. The lenses are currently available in polycarbonate material with Crizal Easy Pro antireflective coating and provide 100% UV protection. Prescribing parameters are sphere (plano to -10 D) and cylinder (plano to -4 D). The 70 mm diameter allows for wide frame selection.
When fitting Stellest lenses, no adjustments to the patient’s spectacle refraction are necessary. Opticians should obtain monocular pupillary distances as well as monocular segment heights. After dispensing, Essilor recommends a 2-week follow-up to ensure adaptation and to make any necessary adjustments, followed by 6-month visits to monitor fit and progression.
Myopia management can be a rewarding and lucrative addition to any practice, and with today's portfolio of options, practitioners are able to help even more patients. By using this month's review of those choices, you will be ready to choose the most appropriate path for your cases. Good luck expanding into this exciting avenue in 2026!
